A single-center, randomized, double-blind, three-way crossover study examining postchallenge glucose responses to human insulin 70/30 and insulin lispro fixed mixtures 75/25 and 50/50 in patients with type 2 diabetes mellitus

Clinical Therapeutics

Volumn 28, Issue 10, 2006, Pages 1649-1657

  Schwartz, Sherwyn ^a   Zagar, Anthony J ^b   Althouse, Sandra K ^b   Pinaire, Jane A ^b   Holcombe, John H ^b  

^a Diabetes and Glandular Disease Clinic   (United States)

^b ELI LILLY AND COMPANY   (United States)

Author keywords

insulin mixtures; pharmacodynamics; postprandial glucose; rapid acting insulin analogues; test meal; type 2 diabetes

Indexed keywords

CARBOHYDRATE; FAT; GLUCOSE; GLYCOSYLATED HEMOGLOBIN; HUMAN INSULIN; INSULIN LISPRO; PROTEIN;

ADULT; AFRICAN AMERICAN; AREA UNDER THE CURVE; ARTICLE; ATTENUATION; BODY MASS; BODY WEIGHT; CALORIC INTAKE; CARBOHYDRATE INTAKE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIABETES CONTROL; DIABETIC PATIENT; DISORIENTATION; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG DOSE COMPARISON; DRUG MIXTURE; DRUG TOLERABILITY; EUROPEAN AMERICAN; FAT INTAKE; FEMALE; GLUCOSE BLOOD LEVEL; HISPANIC; HUMAN; INJECTION SITE REACTION; INSULIN TREATMENT; MALE; MEASUREMENT; NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; PAIN; PROTEIN INTAKE; RANDOMIZED CONTROLLED TRIAL; SINGLE DRUG DOSE; TEST MEAL; TREATMENT RESPONSE; TREMOR; URINARY TRACT INFECTION;

AGED; BLOOD GLUCOSE; CROSS-OVER STUDIES; DIABETES MELLITUS, TYPE 2; DOUBLE-BLIND METHOD; FEMALE; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; MALE; MIDDLE AGED; POSTPRANDIAL PERIOD;

EID: 33751509870     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/j.clinthera.2006.10.017     Document Type: Article

References (26)

1. Brunzell J.D., Robertson R.P., Lerner R.L., et al. Relationships between fasting plasma glucose levels and insulin secretion during intravenous glucose tolerance tests. J Clin Endocrinol Metab 42 (1976) 222-229
2. Kahn S.E. Clinical review 135: The importance of beta-cell failure in the development and progression of type 2 diabetes. J Clin Endocrinol Metab 86 (2001) 4047-4058
3. Pratley R.E., and Weyer C. The role of impaired early insulin secretion in the pathogenesis of type II diabetes mellitus. Diabetologia 44 (2001) 929-945
4. Caumo A., and Luzi L. First-phase insulin secretion: Does it exist in real life? Considerations on shape and function. Am J Physiol Endocrinol Metab 287 (2004) E371-E385
5. Garber A.J. The importance of early insulin secretion and its impact on glycemic regulation. Int J Obes Relat Metab Disord 24 Suppl 3 (2000) S32-S37
6. Del Prato S., Marchetti P., and Bonadonna R.C. Phasic insulin release and metabolic regulation in type 2 diabetes. Diabetes 51 Suppl 1 (2002) S109-S116
7. Riddle M.C. Glycemic management of type 2 diabetes: An emerging strategy with oral agents, insulins, and combinations. Endocrinol Metab Clin North Am 34 (2005) 77-98
8. Turner H.E., and Matthews D.R. The use of fixed-mixture insulins in clinical practice. Eur J Clin Pharmacol 56 (2000) 19-25
9. Bruttomesso D., Pianta A., Mari A., et al. Restoration of early rise in plasma insulin levels improves the glucose tolerance of type 2 diabetic patients. Diabetes 48 (1999) 99-105
10. Heise T., Weyer C., Serwas A., et al. Time-action profiles of novel premixed preparations of insulin lispro and NPL insulin. Diabetes Care 21 (1998) 800-803
11. Report of the Expert Committee on the diagnosis and classification of diabetes mellitus. Diabetes Care 24 Suppl 1 (2001) S5-520
12. [WMA Web site]. World Medical Association Declaration of Helsinki. Recommendations Guiding Medical Doctors in Biomedical Research Involving Human Subjects. Accessed June 15, 2006 (1989), WMA, Ferney-Voltaire, France. http://www.wma.net Accessed June 15, 2006
13. [EMEA Web site]. European Agency for the Evaluation of Medicinal Products. Accessed June 15, 2006. International Conference on Harmonisation-World Health Organization. Guideline for Good Clinical Practice. ICH Topic E6 (2002), WHO, Geneva, Switzerland. http://www.emea.eu.int Accessed June 15, 2006
14. Senn S. Cross-Over Trials in Clinical Research. 2nd ed. (2002), John Wiley & Sons, Hoboken, NJ
15. Koivisto V.A., Tuominen J.A., and Ebeling P. Lispro Mix25 insulin as premeal therapy in type 2 diabetic patients. Diabetes Care 22 (1999) 459-462
16. Roach P., Trautmann M., Arora V., et al., Mix50 Study Group. Improved postprandial blood glucose control and reduced nocturnal hypoglycemia during treatment with two novel insulin lispro-protamine formulations, insulin lispro mix25 and insulin lispro mix50. Clin Ther 21 (1999) 523-534
17. Roach P., Yue L., Arora V., and Humalog Mix25 Study Group. Improved postprandial glycemic con trol during treatment with Humalog mix25, a novel protamine-based insulin lispro formulation. Diabetes Care 22 (1999) 1258-1261
18. Malone J.K., Woodworth J.R., Arora V., et al. Improved postprandial glycemic control with Humalog Mix75/25 aftera standard test meal in patients with type 2 diabetes mellitus. Clin Ther 22 (2000) 222-230
19. Coscelli C., Iacobellis G., Calderini C., et al. Importance of premeal injection time in insulin therapy: Humalog mix25 is convenient for improved post-prandial glycemic control in type 2 diabetic patients with Italian dietary habits. Acta Diabetol 407 (2003) 187-192
20. Herz M., Arora V., Campaigne B.N., et al. Humalog mix25 improves 24-hour plasma glucose profiles compared with the human insulin mixture 30/70 in patients with type 2 diabetes mellitus. S Afr Med J 93 (2003) 219-223
21. Mattoo V., Milicevic Z., Malone J.K., et al., Ramadan Study Group. A comparison of insulin lispro Mix25 and human insulin 30/70 in the treatment of type 2 diabetes during Ramadan. Diabetes Res Clin Pract 59 (2003) 137-143
22. Schernthaner G., Kopp H.P., Ristic S., et al. Metabolic control in patients with type 2 diabetes using Humalog mix50 injected three times daily: Crossover comparison with human insulin 30/70. Horm Metab Res 36 (2004) 188-193
23. Heinemann L., and Anderson Jr. J.H. Measurement of insulin absorption and insulin action. Diabetes Technol Ther 6 (2004) 698-718
24. Perriello G., Pampanelli S., Porcellati F., et al. Insulin aspart improves meal time glycaemic control in pa tients with type 2 diabetes: A randomized, stratified, double-blind and cross-over trial. Diabet Med 22 (2005) 606-611
25. Roach P., Arora V., Campaigne B.N., et al., India Mix25/Mix50 Study Group. Humalog mix50 be fore carbohydrate-rich meals in type 2 diabetes mellitus. Diabetes Obes Metab 5 (2003) 311-316
26. Monnier L., Lapinski H., and Collette C. Contributions of fasting and postprandial plasma glucose increments to the overall diurnal hyperglycemia of type 2 diabetic patients: Variations with increasing levels of HbA(1c). Diabetes Care 26 (2003) 881-885